Leukemia Therapeutics Market Key Players Analysis 2031
Leukemia is a cancer that affects the bone marrow and white blood cells. Leukemia is a rapidly spreading blood cancer that begins in the bone marrow then leads to uncontrolled blood cell growth. Leukemia is emerging as a life-threatening hazard around the globe, among other cancer forms. When a person has leukemia, their bodies produce an excessive number of white blood cells. Chemotherapy, biological therapy, targeted therapy, radiation therapy, and other treatments are common in the fight against leukemia. The leukemia therapeutic market includes a variety of therapies recommended by doctors for the treatment of leukemia.
MARKET SCOPE
The "Global Leukemia Therapeutics Market Analysis to 2031" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the leukemia therapeutics market with detailed market segmentation by type, treatment, mode of administration, molecule type, gender, and geography. The report provides key statistics on the market status of the leading leukemia therapeutics market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
- Based on type, the market is segmented as, CLL, ALL, CML, and AML.
- Treatment is further segmented into chemotherapy; targeted drugs; immunotherapy.
- By mode of administration, the market is segmented into oral, and injectable.
- The leukemia therapeutics market is categorized based on molecule type such as, small molecules, and biologics.
- Based on gender, the market is segmented into males and females.
MARKET DYNAMICS
Drivers:
- Considerable number of treatment options available for the treatment of chronic myeloid leukemia (CML)
- High incidence rate of CML
- Continuous initiatives for product development
Restraints:
- Complexities in Manufacturing
- High Cost of Treatment
- Stringent Regulatory Scenario
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The leukemia therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the leukemia therapeutics market in these regions.
IMPACT OF COVID-19 ON LEUKEMIA THERAPEUTICS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The leukemia therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the leukemia therapeutics market in these regions.
IMPACT OF COVID-19 ON LEUKEMIA THERAPEUTICS MARKET
COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.
MARKET PLAYERS
The report covers key developments in the leukemia therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from leukemia therapeutics market are anticipated to lucrative growth opportunities in the future with the rising demand for leukemia therapeutics in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the leukemia therapeutics market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
- Novartis AG
- AbbVie Inc
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Sanofi
- Pfizer Inc
- Amgen Inc
- Gilead Sciences, Inc.
- Takeda Pharmaceutical Company Limited
- CELGENE CORPORATION
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Leukemia Therapeutics Market - By Type
1.3.2 Leukemia Therapeutics Market - By Treatment
1.3.3 Leukemia Therapeutics Market - By Molecule Type
1.3.4 Leukemia Therapeutics Market - By Mode of Administration
1.3.5 Leukemia Therapeutics Market - By Gender
1.3.6 Leukemia Therapeutics Market - By Region
1.3.6.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. LEUKEMIA THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. LEUKEMIA THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. LEUKEMIA THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. LEUKEMIA THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. LEUKEMIA THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. LEUKEMIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. CHRONIC MYELOID LEUKEMIA
7.3.1. Overview
7.3.2. Chronic Myeloid Leukemia Market Forecast and Analysis
7.4. CHRONIC LYMPHOCYTIC LEUKEMIA
7.4.1. Overview
7.4.2. Chronic Lymphocytic Leukemia Market Forecast and Analysis
7.5. ACUTE LYMPHOCYTIC LEUKEMIA
7.5.1. Overview
7.5.2. Acute Lymphocytic Leukemia Market Forecast and Analysis
7.6. ACUTE MYELOID LEUKEMIA
7.6.1. Overview
7.6.2. Acute Myeloid Leukemia Market Forecast and Analysis
8. LEUKEMIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - TREATMENT
8.1. OVERVIEW
8.2. TREATMENT MARKET FORECASTS AND ANALYSIS
8.3. TARGETED DRUGS AND IMMUNOTHERAPY
8.3.1. Overview
8.3.2. Targeted Drugs And Immunotherapy Market Forecast and Analysis
8.4. CHEMOTHERAPY
8.4.1. Overview
8.4.2. Chemotherapy Market Forecast and Analysis
9. LEUKEMIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - MOLECULE TYPE
9.1. OVERVIEW
9.2. MOLECULE TYPE MARKET FORECASTS AND ANALYSIS
9.3. SMALL MOLECULES
9.3.1. Overview
9.3.2. Small Molecules Market Forecast and Analysis
9.4. BIOLOGICS
9.4.1. Overview
9.4.2. Biologics Market Forecast and Analysis
10. LEUKEMIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - MODE OF ADMINISTRATION
10.1. OVERVIEW
10.2. MODE OF ADMINISTRATION MARKET FORECASTS AND ANALYSIS
10.3. ORAL MODE
10.3.1. Overview
10.3.2. Oral Mode Market Forecast and Analysis
10.4. INJECTABLE MODE
10.4.1. Overview
10.4.2. Injectable Mode Market Forecast and Analysis
11. LEUKEMIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - GENDER
11.1. OVERVIEW
11.2. GENDER MARKET FORECASTS AND ANALYSIS
11.3. MALES
11.3.1. Overview
11.3.2. Males Market Forecast and Analysis
11.4. FEMALES
11.4.1. Overview
11.4.2. Females Market Forecast and Analysis
12. LEUKEMIA THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
12.1. NORTH AMERICA
12.1.1 North America Leukemia Therapeutics Market Overview
12.1.2 North America Leukemia Therapeutics Market Forecasts and Analysis
12.1.3 North America Leukemia Therapeutics Market Forecasts and Analysis - By Type
12.1.4 North America Leukemia Therapeutics Market Forecasts and Analysis - By Treatment
12.1.5 North America Leukemia Therapeutics Market Forecasts and Analysis - By Molecule Type
12.1.6 North America Leukemia Therapeutics Market Forecasts and Analysis - By Mode of Administration
12.1.7 North America Leukemia Therapeutics Market Forecasts and Analysis - By Gender
12.1.8 North America Leukemia Therapeutics Market Forecasts and Analysis - By Countries
12.1.8.1 United States Leukemia Therapeutics Market
12.1.8.1.1 United States Leukemia Therapeutics Market by Type
12.1.8.1.2 United States Leukemia Therapeutics Market by Treatment
12.1.8.1.3 United States Leukemia Therapeutics Market by Molecule Type
12.1.8.1.4 United States Leukemia Therapeutics Market by Mode of Administration
12.1.8.1.5 United States Leukemia Therapeutics Market by Gender
12.1.8.2 Canada Leukemia Therapeutics Market
12.1.8.2.1 Canada Leukemia Therapeutics Market by Type
12.1.8.2.2 Canada Leukemia Therapeutics Market by Treatment
12.1.8.2.3 Canada Leukemia Therapeutics Market by Molecule Type
12.1.8.2.4 Canada Leukemia Therapeutics Market by Mode of Administration
12.1.8.2.5 Canada Leukemia Therapeutics Market by Gender
12.1.8.3 Mexico Leukemia Therapeutics Market
12.1.8.3.1 Mexico Leukemia Therapeutics Market by Type
12.1.8.3.2 Mexico Leukemia Therapeutics Market by Treatment
12.1.8.3.3 Mexico Leukemia Therapeutics Market by Molecule Type
12.1.8.3.4 Mexico Leukemia Therapeutics Market by Mode of Administration
12.1.8.3.5 Mexico Leukemia Therapeutics Market by Gender
12.2. EUROPE
12.2.1 Europe Leukemia Therapeutics Market Overview
12.2.2 Europe Leukemia Therapeutics Market Forecasts and Analysis
12.2.3 Europe Leukemia Therapeutics Market Forecasts and Analysis - By Type
12.2.4 Europe Leukemia Therapeutics Market Forecasts and Analysis - By Treatment
12.2.5 Europe Leukemia Therapeutics Market Forecasts and Analysis - By Molecule Type
12.2.6 Europe Leukemia Therapeutics Market Forecasts and Analysis - By Mode of Administration
12.2.7 Europe Leukemia Therapeutics Market Forecasts and Analysis - By Gender
12.2.8 Europe Leukemia Therapeutics Market Forecasts and Analysis - By Countries
12.2.8.1 Germany Leukemia Therapeutics Market
12.2.8.1.1 Germany Leukemia Therapeutics Market by Type
12.2.8.1.2 Germany Leukemia Therapeutics Market by Treatment
12.2.8.1.3 Germany Leukemia Therapeutics Market by Molecule Type
12.2.8.1.4 Germany Leukemia Therapeutics Market by Mode of Administration
12.2.8.1.5 Germany Leukemia Therapeutics Market by Gender
12.2.8.2 France Leukemia Therapeutics Market
12.2.8.2.1 France Leukemia Therapeutics Market by Type
12.2.8.2.2 France Leukemia Therapeutics Market by Treatment
12.2.8.2.3 France Leukemia Therapeutics Market by Molecule Type
12.2.8.2.4 France Leukemia Therapeutics Market by Mode of Administration
12.2.8.2.5 France Leukemia Therapeutics Market by Gender
12.2.8.3 Italy Leukemia Therapeutics Market
12.2.8.3.1 Italy Leukemia Therapeutics Market by Type
12.2.8.3.2 Italy Leukemia Therapeutics Market by Treatment
12.2.8.3.3 Italy Leukemia Therapeutics Market by Molecule Type
12.2.8.3.4 Italy Leukemia Therapeutics Market by Mode of Administration
12.2.8.3.5 Italy Leukemia Therapeutics Market by Gender
12.2.8.4 Spain Leukemia Therapeutics Market
12.2.8.4.1 Spain Leukemia Therapeutics Market by Type
12.2.8.4.2 Spain Leukemia Therapeutics Market by Treatment
12.2.8.4.3 Spain Leukemia Therapeutics Market by Molecule Type
12.2.8.4.4 Spain Leukemia Therapeutics Market by Mode of Administration
12.2.8.4.5 Spain Leukemia Therapeutics Market by Gender
12.2.8.5 United Kingdom Leukemia Therapeutics Market
12.2.8.5.1 United Kingdom Leukemia Therapeutics Market by Type
12.2.8.5.2 United Kingdom Leukemia Therapeutics Market by Treatment
12.2.8.5.3 United Kingdom Leukemia Therapeutics Market by Molecule Type
12.2.8.5.4 United Kingdom Leukemia Therapeutics Market by Mode of Administration
12.2.8.5.5 United Kingdom Leukemia Therapeutics Market by Gender
12.3. ASIA-PACIFIC
12.3.1 Asia-Pacific Leukemia Therapeutics Market Overview
12.3.2 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis
12.3.3 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis - By Type
12.3.4 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis - By Treatment
12.3.5 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis - By Molecule Type
12.3.6 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis - By Mode of Administration
12.3.7 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis - By Gender
12.3.8 Asia-Pacific Leukemia Therapeutics Market Forecasts and Analysis - By Countries
12.3.8.1 Australia Leukemia Therapeutics Market
12.3.8.1.1 Australia Leukemia Therapeutics Market by Type
12.3.8.1.2 Australia Leukemia Therapeutics Market by Treatment
12.3.8.1.3 Australia Leukemia Therapeutics Market by Molecule Type
12.3.8.1.4 Australia Leukemia Therapeutics Market by Mode of Administration
12.3.8.1.5 Australia Leukemia Therapeutics Market by Gender
12.3.8.2 China Leukemia Therapeutics Market
12.3.8.2.1 China Leukemia Therapeutics Market by Type
12.3.8.2.2 China Leukemia Therapeutics Market by Treatment
12.3.8.2.3 China Leukemia Therapeutics Market by Molecule Type
12.3.8.2.4 China Leukemia Therapeutics Market by Mode of Administration
12.3.8.2.5 China Leukemia Therapeutics Market by Gender
12.3.8.3 India Leukemia Therapeutics Market
12.3.8.3.1 India Leukemia Therapeutics Market by Type
12.3.8.3.2 India Leukemia Therapeutics Market by Treatment
12.3.8.3.3 India Leukemia Therapeutics Market by Molecule Type
12.3.8.3.4 India Leukemia Therapeutics Market by Mode of Administration
12.3.8.3.5 India Leukemia Therapeutics Market by Gender
12.3.8.4 Japan Leukemia Therapeutics Market
12.3.8.4.1 Japan Leukemia Therapeutics Market by Type
12.3.8.4.2 Japan Leukemia Therapeutics Market by Treatment
12.3.8.4.3 Japan Leukemia Therapeutics Market by Molecule Type
12.3.8.4.4 Japan Leukemia Therapeutics Market by Mode of Administration
12.3.8.4.5 Japan Leukemia Therapeutics Market by Gender
12.3.8.5 South Korea Leukemia Therapeutics Market
12.3.8.5.1 South Korea Leukemia Therapeutics Market by Type
12.3.8.5.2 South Korea Leukemia Therapeutics Market by Treatment
12.3.8.5.3 South Korea Leukemia Therapeutics Market by Molecule Type
12.3.8.5.4 South Korea Leukemia Therapeutics Market by Mode of Administration
12.3.8.5.5 South Korea Leukemia Therapeutics Market by Gender
12.4. MIDDLE EAST AND AFRICA
12.4.1 Middle East and Africa Leukemia Therapeutics Market Overview
12.4.2 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis
12.4.3 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis - By Type
12.4.4 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis - By Treatment
12.4.5 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis - By Molecule Type
12.4.6 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis - By Mode of Administration
12.4.7 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis - By Gender
12.4.8 Middle East and Africa Leukemia Therapeutics Market Forecasts and Analysis - By Countries
12.4.8.1 South Africa Leukemia Therapeutics Market
12.4.8.1.1 South Africa Leukemia Therapeutics Market by Type
12.4.8.1.2 South Africa Leukemia Therapeutics Market by Treatment
12.4.8.1.3 South Africa Leukemia Therapeutics Market by Molecule Type
12.4.8.1.4 South Africa Leukemia Therapeutics Market by Mode of Administration
12.4.8.1.5 South Africa Leukemia Therapeutics Market by Gender
12.4.8.2 Saudi Arabia Leukemia Therapeutics Market
12.4.8.2.1 Saudi Arabia Leukemia Therapeutics Market by Type
12.4.8.2.2 Saudi Arabia Leukemia Therapeutics Market by Treatment
12.4.8.2.3 Saudi Arabia Leukemia Therapeutics Market by Molecule Type
12.4.8.2.4 Saudi Arabia Leukemia Therapeutics Market by Mode of Administration
12.4.8.2.5 Saudi Arabia Leukemia Therapeutics Market by Gender
12.4.8.3 U.A.E Leukemia Therapeutics Market
12.4.8.3.1 U.A.E Leukemia Therapeutics Market by Type
12.4.8.3.2 U.A.E Leukemia Therapeutics Market by Treatment
12.4.8.3.3 U.A.E Leukemia Therapeutics Market by Molecule Type
12.4.8.3.4 U.A.E Leukemia Therapeutics Market by Mode of Administration
12.4.8.3.5 U.A.E Leukemia Therapeutics Market by Gender
12.5. SOUTH AND CENTRAL AMERICA
12.5.1 South and Central America Leukemia Therapeutics Market Overview
12.5.2 South and Central America Leukemia Therapeutics Market Forecasts and Analysis
12.5.3 South and Central America Leukemia Therapeutics Market Forecasts and Analysis - By Type
12.5.4 South and Central America Leukemia Therapeutics Market Forecasts and Analysis - By Treatment
12.5.5 South and Central America Leukemia Therapeutics Market Forecasts and Analysis - By Molecule Type
12.5.6 South and Central America Leukemia Therapeutics Market Forecasts and Analysis - By Mode of Administration
12.5.7 South and Central America Leukemia Therapeutics Market Forecasts and Analysis - By Gender
12.5.8 South and Central America Leukemia Therapeutics Market Forecasts and Analysis - By Countries
12.5.8.1 Brazil Leukemia Therapeutics Market
12.5.8.1.1 Brazil Leukemia Therapeutics Market by Type
12.5.8.1.2 Brazil Leukemia Therapeutics Market by Treatment
12.5.8.1.3 Brazil Leukemia Therapeutics Market by Molecule Type
12.5.8.1.4 Brazil Leukemia Therapeutics Market by Mode of Administration
12.5.8.1.5 Brazil Leukemia Therapeutics Market by Gender
12.5.8.2 Argentina Leukemia Therapeutics Market
12.5.8.2.1 Argentina Leukemia Therapeutics Market by Type
12.5.8.2.2 Argentina Leukemia Therapeutics Market by Treatment
12.5.8.2.3 Argentina Leukemia Therapeutics Market by Molecule Type
12.5.8.2.4 Argentina Leukemia Therapeutics Market by Mode of Administration
12.5.8.2.5 Argentina Leukemia Therapeutics Market by Gender
13. IMPACT OF COVID-19 PANDEMIC ON GLOBAL LEUKEMIA THERAPEUTICS MARKET
13.1 North America
13.2 Europe
13.3 Asia-Pacific
13.4 Middle East and Africa
13.5 South and Central America
14. INDUSTRY LANDSCAPE
14.1. MERGERS AND ACQUISITIONS
14.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
14.3. NEW PRODUCT LAUNCHES
14.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
15. LEUKEMIA THERAPEUTICS MARKET, KEY COMPANY PROFILES
15.1. NOVARTIS AG
15.1.1. Key Facts
15.1.2. Business Description
15.1.3. Products and Services
15.1.4. Financial Overview
15.1.5. SWOT Analysis
15.1.6. Key Developments
15.2. ABBVIE INC
15.2.1. Key Facts
15.2.2. Business Description
15.2.3. Products and Services
15.2.4. Financial Overview
15.2.5. SWOT Analysis
15.2.6. Key Developments
15.3. BRISTOL-MYERS SQUIBB COMPANY
15.3.1. Key Facts
15.3.2. Business Description
15.3.3. Products and Services
15.3.4. Financial Overview
15.3.5. SWOT Analysis
15.3.6. Key Developments
15.4. F. HOFFMANN-LA ROCHE LTD
15.4.1. Key Facts
15.4.2. Business Description
15.4.3. Products and Services
15.4.4. Financial Overview
15.4.5. SWOT Analysis
15.4.6. Key Developments
15.5. SANOFI
15.5.1. Key Facts
15.5.2. Business Description
15.5.3. Products and Services
15.5.4. Financial Overview
15.5.5. SWOT Analysis
15.5.6. Key Developments
15.6. PFIZER INC.
15.6.1. Key Facts
15.6.2. Business Description
15.6.3. Products and Services
15.6.4. Financial Overview
15.6.5. SWOT Analysis
15.6.6. Key Developments
15.7. AMGEN INC
15.7.1. Key Facts
15.7.2. Business Description
15.7.3. Products and Services
15.7.4. Financial Overview
15.7.5. SWOT Analysis
15.7.6. Key Developments
15.8. GILEAD SCIENCES, INC.
15.8.1. Key Facts
15.8.2. Business Description
15.8.3. Products and Services
15.8.4. Financial Overview
15.8.5. SWOT Analysis
15.8.6. Key Developments
15.9. TAKEDA PHARMACEUTICAL COMPANY LIMITED
15.9.1. Key Facts
15.9.2. Business Description
15.9.3. Products and Services
15.9.4. Financial Overview
15.9.5. SWOT Analysis
15.9.6. Key Developments
15.10. CELGENE CORPORATION
15.10.1. Key Facts
15.10.2. Business Description
15.10.3. Products and Services
15.10.4. Financial Overview
15.10.5. SWOT Analysis
15.10.6. Key Developments
16. APPENDIX
16.1. ABOUT THE INSIGHT PARTNERS
16.2. GLOSSARY OF TERMS
1. Novartis AG
2. AbbVie Inc
3. Bristol-Myers Squibb Company
4. F. Hoffmann-La Roche Ltd
5. Sanofi
6. Pfizer Inc
7. Amgen Inc
8. Gilead Sciences, Inc.
9. Takeda Pharmaceutical Company Limited
10. CELGENE CORPORATION
11. AstraZeneca plc
12. Incyte Corp
13. Johnson & Johnson
14. Merck & Co., Inc.
15. Clovis Oncology
16. Boehringer Ingelheim International GmbH
17. GlaxoSmithKline plc
18. Exelixis, Inc
19. MorphoSys AG
20. Ono Pharmaceutical Co.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For